Polymorphisms in IGF2/H19 Gene Locus are Associated with Platinum-Based Chemotherapeutic Response in Chinese Patients with Epithelial Ovarian Cancer
- 23 January 2019
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 20 (3) , 179-188
Abstract
Aim: The present study aimed to assess the association between IGF2/H19 genetic variants and susceptibility to platinum-based chemotherapy in epithelial ovarian cancer (EOC). Methods: A total of 43 platinum-resistant (PR) and 138 platinum-sensitive (PS) EOC patients were recruited in our study. 21 polymorphisms in IGF2/H19 locus were genotyped by Sequenom MassARRAY assay. Results: The frequencies of GG genotype in both rs3842761(C/G) and rs4244809(A/G) were significantly lower in PR group compared with those in PS group (9.76 vs 23.36%, p =0.049; 9.76 vs 26.09%, p =0.045; respectively). Compared with the AA genotype, rs4244809 GG genotype was associated with significantly reduced risk of platinum resistance (adjusted OR: 0.30; 95% CI: 0.10-0.91; p =0.033). Further stratified analyses revealed that the SNPs of rs3842761 and rs4244809 were greatly related to PR risk in FIGO stage III-IV (rs3842761GG/CC+CG: adjusted OR: 0.15; 95% CI: 0.02-1.21; rs4244809 GG/AA+AG: adjusted OR: 0.24; 95% CI: 0.07-0.84; respectively) and serous adenocarcinoma subgroups (rs3842761 GG/CC+CG: adjusted OR: 0.21; 95% CI: 0.05-0.94; rs4244809 GG/AA+AG: adjusted OR: 0.19; 95% CI: 0.04-0.5; respectively), while rs7924316 polymorphism was associated with reduced risk of PR in serous adenocarcinoma subgroup as analyzed by a recessive model (rs7924316 GG/TT+TG: adjusted OR: 0.22; 95% CI: 0.05-0.98). In addition, both TCT haplotypes of rs3741206/rs3842761/rs7924316 and TC haplotype of rs3741206/rs3842761 were associated with elevated risk of PR (for the TCT haplotype of rs3741206/rs3842761/rs7924316: p =0.049; OR: 1.69; 95% CI: 1.00-2.87; for the TC haplotype of rs3741206/rs3842761: p =0.044; OR: 1.71; 95% CI: 1.01-2.88). Conclusion: These results suggest that polymorphisms in IGF2/H19 gene locus are associated with PR risk in EOC.Keywords
Funding Information
- National Scientific Foundation of China (81673516, 81402968, 81603197)
- Hunan Natural Science Foundation (2017JJ3503)
This publication has 34 references indexed in Scilit:
- Associations Between Paternally Transmitted Fetal IGF2 Variants and Maternal Circulating Glucose Concentrations in PregnancyDiabetes, 2011
- Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomasThe Journal of Pathology, 2011
- Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer riskHuman Molecular Genetics, 2011
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell CarcinomaScience, 2010
- Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian CancerClinical Cancer Research, 2010
- Epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2008
- Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cellsOncogene, 2007
- An association between variants in the IGF2 gene and Beckwith-Wiedemann syndrome: interaction between genotype and epigenotypeHuman Molecular Genetics, 2003
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996